Sean Bohen, Olema president & CEO
May 11, 2023 10:57 AM EDT
R&D

Ole­ma gives small up­date to breast can­cer drug at cen­ter of lay­offs, 2021 da­ta leak

Kyle LaHucik

Senior Reporter

Ole­ma Phar­ma­ceu­ti­cals is out with more da­ta on its in­ves­ti­ga­tion­al breast can­cer drug, for which it shed 25% of its work­force two months ago to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Genen­tech vet launch­es ADC start­up with $20M

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times